{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:53:17Z","timestamp":1775479997186,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2320-B-038-045"],"award-info":[{"award-number":["112-2320-B-038-045"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Temozolomide (TMZ) resistance in glioblastoma (GBM) remains a critical barrier to treatment success, driven by O\n                      <jats:sup>6<\/jats:sup>\n                      -methylguanine-DNA methyltransferase (MGMT) overexpression, glioma stem cell (GSC) persistence, and redox adaptation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed cp8, a first-in-class abiraterone-based histone deacetylase (HDAC) inhibitor, to simultaneously target these resistance mechanisms. The orthotopic mouse models were used to evaluate the efficacy of cp8 compared to SAHA (vorinostat). The mouse survival period was recorded, and the tumor growth was monitored using the IVIS imaging system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cp8 demonstrated approximately tenfold greater potency than SAHA, with IC\u2085\u2080 values\u2009\u2264\u20093\u00a0\u00b5M against TMZ-resistant GBM cells (compared with\u2009\u2265\u200930\u00a0\u00b5M for SAHA). Transcriptomic analysis revealed a unique ability of cp8 to upregulate filaggrin (FLG), a structural protein whose expression correlated with improved patient survival in TCGA and CGGA datasets (p\u2009=\u20090.001). Functional studies showed that FLG knockdown increased GSC-associated markers (Oct4, 2.1-fold; SOX2, 1.8-fold) and enhanced TMZ resistance, whereas cp8 treatment reduced MGMT protein expression by 68% and significantly decreased glioma sphere size by 54% (p\u2009&lt;\u20090.01). In orthotopic models, cp8 extended median survival to 59\u00a0days compared with 34\u00a0days for controls (p\u2009&lt;\u20090.001) and 49\u00a0days for SAHA (p\u2009&lt;\u20090.01), while reducing tumor volume by 72% (p\u2009&lt;\u20090.001) without systemic toxicity. Mechanistically, dual inhibition of HDAC6 and CYP17A1 by cp8 disrupted redox homeostasis and stemness-associated pathways, leading to altered ROS metabolism, reduced MGMT expression, and attenuation of GSC-driven tumor growth while restoring FLG-mediated tumor suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study establishes FLG as a novel therapeutic target in GBM and validates the suppressive efficacy of cp8 on the characteristics of TMZ resistance, highlighting the translational potential as a multitargeted therapy against TMZ-resistant GBM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12929-026-01241-2","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:13:20Z","timestamp":1775470400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor"],"prefix":"10.1186","volume":"33","author":[{"given":"Hoang Yen","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Yi","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-I.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"6","key":"1241_CR1","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1158\/0008-5472.CAN-10-3213","volume":"71","author":"EM Goellner","year":"2011","unstructured":"Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, et al. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res. 2011;71(6):2308\u201317.","journal-title":"Cancer Res"},{"key":"1241_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133161","author":"NF Brown","year":"2022","unstructured":"Brown NF, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S, et al. Survival outcomes and prognostic factors in glioblastoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14133161.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1241_CR3","first-page":"17","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4(1):17\u201343.","journal-title":"Cancer Drug Resist"},{"issue":"7","key":"1241_CR4","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierza\u0144ski","year":"2024","unstructured":"Jezierza\u0144ski M, Nafalska N, Stopyra M, Furgo\u0142 T, Miciak M, Kabut J, et al. Temozolomide (TMZ) in the treatment of glioblastoma multiforme-a literature review and clinical outcomes. Curr Oncol. 2024;31(7):3994\u20134002.","journal-title":"Curr Oncol"},{"issue":"10","key":"1241_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","volume":"58","author":"S Jiapaer","year":"2018","unstructured":"Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir (Tokyo). 2018;58(10):405\u201321.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"2","key":"1241_CR6","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochimica et Biophysica Acta (BBA). 2021;1876(2):188616.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"1241_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68902-w","volume":"14","author":"C Duan","year":"2024","unstructured":"Duan C, He B, Wang Y, Liu W, Bao W, Yu L, et al. Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT. Sci Rep. 2024;14(1):20199.","journal-title":"Sci Rep"},{"issue":"1","key":"1241_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00717-7","volume":"28","author":"C-H Chien","year":"2021","unstructured":"Chien C-H, Hsueh W-T, Chuang J-Y, Chang K-Y. Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. J Biomed Sci. 2021;28(1):18.","journal-title":"J Biomed Sci"},{"issue":"3","key":"1241_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/neuonc\/noaa198","volume":"23","author":"E Nie","year":"2021","unstructured":"Nie E, Jin X, Miao F, Yu T, Zhi T, Shi Z, et al. TGF-\u03b21 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. Neuro Oncol. 2021;23(3):435\u201346.","journal-title":"Neuro Oncol"},{"issue":"8","key":"1241_CR10","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/brain\/awz202","volume":"142","author":"GZ Yi","year":"2019","unstructured":"Yi GZ, Huang G, Guo M, Zhang X, Wang H, Deng S, et al. Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain. 2019;142(8):2352\u201366.","journal-title":"Brain"},{"issue":"2","key":"1241_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaci.2012.12.668","volume":"131","author":"MA McAleer","year":"2013","unstructured":"McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280\u201391.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1241_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/sj.jid.5701190","volume":"128","author":"N Novak","year":"2008","unstructured":"Novak N, Baurecht H, Sch\u00e4fer T, Rodriguez E, Wagenpfeil S, Klopp N, et al. Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol. 2008;128(6):1430\u20135.","journal-title":"J Invest Dermatol"},{"issue":"14","key":"1241_CR13","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMra1011040","volume":"365","author":"AD Irvine","year":"2011","unstructured":"Irvine AD, McLean WHI, Leung DYM. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"1241_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaad.2021.09.068","volume":"87","author":"A Adelanwa","year":"2022","unstructured":"Adelanwa A, Yousaf A, Fang W, Kolodney MS. Common filaggrin gene loss-of-function variants are associated with skin cancer risk. J Am Acad Dermatol. 2022;87(2):458\u201360.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1241_CR15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.21037\/tau-22-573","volume":"11","author":"L Chen","year":"2022","unstructured":"Chen L, Huang X, Xiong L, Chen W, An L, Wang H, et al. Analysis of prognostic oncogene filaggrin (FLG) wild-type subtype and its implications for immune checkpoint blockade therapy in bladder urothelial carcinoma. Transl Androl Urol. 2022;11(10):1419\u201332.","journal-title":"Transl Androl Urol"},{"key":"1241_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.815450","volume":"9","author":"H Chen","year":"2022","unstructured":"Chen H, Zhao L, Liu J, Zhou H, Wang X, Fang X, et al. Bioinformatic analyzes of the association between upregulated expression of JUN gene via APOBEC-induced FLG gene mutation and prognosis of cervical cancer. Front Med Lausanne. 2022;9:815450.","journal-title":"Front Med Lausanne"},{"issue":"6","key":"1241_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099437","volume":"9","author":"T Skaaby","year":"2014","unstructured":"Skaaby T, Husemoen LL, J\u00f8rgensen T, Johansen JD, Menn\u00e9 T, Szecsi PB, et al. Associations of filaggrin gene loss-of-function variants and human papillomavirus-related cancer and pre-cancer in Danish adults. PLoS ONE. 2014;9(6):e99437.","journal-title":"PLoS ONE"},{"issue":"12","key":"1241_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1101\/gad.261982.115","volume":"29","author":"JD Lathia","year":"2015","unstructured":"Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015;29(12):1203\u201317.","journal-title":"Genes Dev"},{"issue":"7","key":"1241_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1586\/14737175.2015.1051968","volume":"15","author":"B Auffinger","year":"2015","unstructured":"Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother. 2015;15(7):741\u201352.","journal-title":"Expert Rev Neurother"},{"key":"1241_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061308","author":"H Kang","year":"2022","unstructured":"Kang H, Lee H, Kim D, Kim B, Kang J, Kim HY, et al. Targeting glioblastoma stem cells to overcome chemoresistance: an overview of current therapeutic strategies. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10061308.","journal-title":"Biomedicines"},{"issue":"1","key":"1241_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05301-9","volume":"22","author":"J White","year":"2024","unstructured":"White J, White MPJ, Wickremesekera A, Peng L, Gray C. The tumour microenvironment, treatment resistance and recurrence in glioblastoma. J Transl Med. 2024;22(1):540.","journal-title":"J Transl Med"},{"issue":"5","key":"1241_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/emboj.2011.10","volume":"30","author":"L Cheng","year":"2011","unstructured":"Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 2011;30(5):800\u201313.","journal-title":"EMBO J"},{"issue":"7","key":"1241_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/cdd.2014.31","volume":"21","author":"B Auffinger","year":"2014","unstructured":"Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 2014;21(7):1119\u201331.","journal-title":"Cell Death Differ"},{"issue":"3","key":"1241_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","volume":"4","author":"AM Bleau","year":"2009","unstructured":"Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226\u201335.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"1241_CR25","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.biomaterials.2011.10.071","volume":"33","author":"YP Yang","year":"2012","unstructured":"Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials. 2012;33(5):1462\u201376.","journal-title":"Biomaterials"},{"issue":"5","key":"1241_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.31","volume":"6","author":"JY Chuang","year":"2017","unstructured":"Chuang JY, Lo WL, Ko CY, Chou SY, Chen RM, Chang KY, et al. Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma. Oncogenesis. 2017;6(5):e339.","journal-title":"Oncogenesis"},{"key":"1241_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091378","author":"HY Lin","year":"2019","unstructured":"Lin HY, Ko CY, Kao TJ, Yang WB, Tsai YT, Chuang JY, et al. CYP17A1 maintains the survival of glioblastomas by regulating SAR1-mediated endoplasmic reticulum health and redox homeostasis. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091378.","journal-title":"Cancers (Basel)"},{"key":"1241_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216666","volume":"586","author":"R Sharma","year":"2024","unstructured":"Sharma R, Chiang YH, Chen HC, Lin HY, Yang WB, Nepali K, et al. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Lett. 2024;586:216666.","journal-title":"Cancer Lett"},{"key":"1241_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101413","volume":"30","author":"TC Chen","year":"2020","unstructured":"Chen TC, Chuang JY, Ko CY, Kao TJ, Yang PY, Yu CH, et al. AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-mediated redox homeostasis. Redox Biol. 2020;30:101413.","journal-title":"Redox Biol"},{"issue":"10","key":"1241_CR30","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/neuonc\/noaa103","volume":"22","author":"WB Yang","year":"2020","unstructured":"Yang WB, Hsu CC, Hsu TI, Liou JP, Chang KY, Chen PY, et al. Increased activation of HDAC1\/2\/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma. Neuro-oncol. 2020;22(10):1439\u201351.","journal-title":"Neuro-oncol"},{"key":"1241_CR31","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.redox.2017.08.005","volume":"13","author":"KY Chang","year":"2017","unstructured":"Chang KY, Hsu TI, Hsu CC, Tsai SY, Liu JJ, Chou SW, et al. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O(6)-methylguanine-DNA methyltransferase. Redox Biol. 2017;13:655\u201364.","journal-title":"Redox Biol"},{"issue":"11","key":"1241_CR32","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"key":"1241_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jviromet.2014.04.013","volume":"205","author":"HY Lin","year":"2014","unstructured":"Lin HY, Liou CJ, Cheng YH, Hsu HC, Yiu JC, Chiou PP, et al. Development and application of a monoclonal antibody against grouper iridovirus (GIV) major capsid protein. J Virol Methods. 2014;205:31\u20137.","journal-title":"J Virol Methods"},{"issue":"3","key":"1241_CR34","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1021\/acs.jmedchem.4c02086","volume":"68","author":"IC Chen","year":"2025","unstructured":"Chen IC, Lin HY, Liu ZY, Cheng WJ, Yeh TY, Yang WB, et al. Repurposing linezolid in conjunction with histone deacetylase inhibitor access in the realm of glioblastoma therapies. J Med Chem. 2025;68(3):2779\u2013803.","journal-title":"J Med Chem"},{"issue":"1","key":"1241_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12974-025-03551-y","volume":"22","author":"H Liang","year":"2025","unstructured":"Liang H, Yang Q, Zhong B, Li D, Wu F, Zhang J, et al. IL-1\u03b2(+) tumor-associated macrophages accelerate Glioblastoma progression by amplifying the PGE2-EP4 signaling. J Neuroinflammation. 2025;22(1):233.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"1241_CR36","first-page":"4095","volume":"16","author":"AJ West","year":"2018","unstructured":"West AJ, Tsui V, Stylli SS, Nguyen HPT, Morokoff AP, Kaye AH, et al. The role of interleukin-6-STAT3 signalling in glioblastoma. Oncol Lett. 2018;16(4):4095\u2013104.","journal-title":"Oncol Lett"},{"issue":"4","key":"1241_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/14728222.2020.1736558","volume":"24","author":"A Jimenez-Pascual","year":"2020","unstructured":"Jimenez-Pascual A, Mitchell K, Siebzehnrubl FA, Lathia JD. FGF2: a novel druggable target for glioblastoma? Expert Opin Ther Targets. 2020;24(4):311\u20138.","journal-title":"Expert Opin Ther Targets"},{"issue":"42","key":"1241_CR38","doi-asserted-by":"publisher","first-page":"E2875","DOI":"10.1073\/pnas.1203659109","volume":"109","author":"L Blau","year":"2012","unstructured":"Blau L, Knirsh R, Ben-Dror I, Oren S, Kuphal S, Hau P, et al. Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation. Proc Natl Acad Sci U S A. 2012;109(42):E2875-e2884.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1241_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166207","volume":"13","author":"M Teraiya","year":"2023","unstructured":"Teraiya M, Perreault H, Chen VC. An overview of Glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance? Front Oncol. 2023;13:1166207.","journal-title":"Front Oncol"},{"key":"1241_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113338","volume":"217","author":"K Nepali","year":"2021","unstructured":"Nepali K, Hsu T-I, Hsieh C-M, Lo W-L, Lai M-J, Hsu K-C, et al. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: a preliminary attempt to unravel the enigma of Glioblastoma. Eur J Med Chem. 2021;217:113338.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"1241_CR41","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s12035-018-1221-7","volume":"56","author":"WB Yang","year":"2019","unstructured":"Yang WB, Chuang JY, Ko CY, Chang WC, Hsu TI. Dehydroepiandrosterone induces Temozolomide resistance through modulating phosphorylation and acetylation of Sp1 in Glioblastoma. Mol Neurobiol. 2019;56(4):2301\u201313.","journal-title":"Mol Neurobiol"},{"issue":"5-6","key":"1241_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","volume":"50","author":"SE Barrie","year":"1994","unstructured":"Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17-20 lyase). J Steroid Biochem Mol Biol. 1994;50(5\u20136):267\u201373.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"1241_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41419-020-2586-x","volume":"11","author":"J Auzmendi-Iriarte","year":"2020","unstructured":"Auzmendi-Iriarte J, Saenz-Anto\u00f1anzas A, Mikelez-Alonso I, Carrasco-Garcia E, Tellaetxe-Abete M, Lawrie CH, et al. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis. 2020;11(6):417.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1241_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12929-016-0296-6","volume":"23","author":"CC Hsu","year":"2016","unstructured":"Hsu CC, Chang WC, Hsu TI, Liu JJ, Yeh SH, Wang JY, et al. Suberoylanilide hydroxamic acid represses glioma stem-like cells. J Biomed Sci. 2016;23(1):81.","journal-title":"J Biomed Sci"},{"issue":"10","key":"1241_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41419-021-04182-w","volume":"12","author":"W-B Yang","year":"2021","unstructured":"Yang W-B, Wu A-C, Hsu T-I, Liou J-P, Lo W-L, Chang K-Y, et al. Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells. Cell Death Dis. 2021;12(10):884.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1241_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30\u20139.","journal-title":"J Clin Invest"},{"issue":"11","key":"1241_CR47","doi-asserted-by":"publisher","first-page":"18577","DOI":"10.18632\/oncotarget.14612","volume":"8","author":"DH Lee","year":"2017","unstructured":"Lee DH, Ryu HW, Won HR, Kwon SH. Advances in epigenetic glioblastoma therapy. Oncotarget. 2017;8(11):18577\u201389.","journal-title":"Oncotarget"},{"issue":"21","key":"1241_CR48","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.34974","volume":"129","author":"R Parveen","year":"2023","unstructured":"Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372\u201380.","journal-title":"Cancer"},{"issue":"1","key":"1241_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.566","volume":"6","author":"E Singer","year":"2015","unstructured":"Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 2015;6(1):e1601.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1241_CR50","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1038\/s41467-021-24108-6","volume":"12","author":"H Huang","year":"2021","unstructured":"Huang H, Zhang S, Li Y, Liu Z, Mi L, Cai Y, et al. Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance. Nat Commun. 2021;12(1):3720.","journal-title":"Nat Commun"},{"issue":"6","key":"1241_CR51","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/bjd.12969","volume":"171","author":"T Skaaby","year":"2014","unstructured":"Skaaby T, Husemoen LL, Thyssen JP, Meldgaard M, Thuesen BH, Pisinger C, et al. Filaggrin loss-of-function mutations and incident cancer: a population-based study. Br J Dermatol. 2014;171(6):1407\u201314.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1241_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15130","volume":"33","author":"CM Khatib","year":"2024","unstructured":"Khatib CM, Klein-Petersen AW, R\u00f8nnstad ATM, Egeberg A, Christensen MO, Silverberg JI, et al. Increased loss-of-function filaggrin gene mutation prevalence in atopic dermatitis patients across northern latitudes indicates genetic fitness: a systematic review and meta-analysis. Exp Dermatol. 2024;33(7):e15130.","journal-title":"Exp Dermatol"},{"issue":"37","key":"1241_CR53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2123451119","volume":"119","author":"SS Ahn","year":"2022","unstructured":"Ahn SS, Yeo H, Jung E, Lim Y, Lee YH, Shin SY. FRA1:c-JUN:HDAC1 complex down-regulates filaggrin expression upon TNF\u03b1 and IFN\u03b3 stimulation in keratinocytes. Proc Natl Acad Sci U S A. 2022;119(37):e2123451119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1241_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1105678","volume":"10","author":"AA Paul","year":"2023","unstructured":"Paul AA, Szulc NA, Kobiela A, Brown SJ, Pokrzywa W, Gutowska-Owsiak D. In silico analysis of the profilaggrin sequence indicates alterations in the stability, degradation route, and intracellular protein fate in filaggrin null mutation carriers. Front Mol Biosci. 2023;10:1105678.","journal-title":"Front Mol Biosci"},{"key":"1241_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031455","author":"JK Hoober","year":"2022","unstructured":"Hoober JK, Eggink LL. The Discovery and Function of Filaggrin. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031455.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-026-01241-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:02:50Z","timestamp":1775476970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-026-01241-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1186\/s12929-026-01241-2","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that the submission represents original work that has not been published previously and is not currently being considered or submitted to another journal, until a decision has been made. Also, we confirm that each author has seen and approved the contents of the submitted manuscript. This manuscript has the permission from the institutional IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}